BackgroundNon-steroidal anti-inflammatory (NSAID) medication could reduce dementia risk due to anti-inflammatory and possibly amyloid-lowering properties. However, the results of observational studies and short-term randomized-controlled trials have been inconsistent, and duration and dose–response relationships are still unclear.MethodsWe included 11,745 dementia-free participants from the prospective population-based Rotterdam Study (59.5% female, mean age 66.2 years). NSAID use from 1991… Continue reading Long-Term Exposure to Non-Steroidal Anti-Inflammatory Medication in Relation to #Dementia Risk
Tag: NSAIDS
COVID-19 Early Treatment with Non-Steroidal AntiInflammatory Drugs Reduces Hospitalizations andSymptom Duration
BackgroundAt the beginning of the SARS-CoV-2 pandemic we stated that,given the new virus and the little-known disease it caused, in theabsence of Evidence-Based Medicine indications, patients shouldhave been treated with drugs already available, useful to counteractthe pathophysiology of the COVID-19 [1]. Recent literature hasconfirmed that this could be a successful approach, demonstratingthat an early treatment… Continue reading COVID-19 Early Treatment with Non-Steroidal AntiInflammatory Drugs Reduces Hospitalizations andSymptom Duration
Non-steroidal anti-inflammatory drug use and outcomes of #COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study
Early in the pandemic it was suggested that pre-existing use of non-steroidal anti-inflammatory drugs (NSAIDs) could lead to increased disease severity in patients with COVID-19. NSAIDs are an important analgesic, particularly in those with rheumatological disease, and are widely available to the general public without prescription. Evidence from community studies, administrative data, and small studies… Continue reading Non-steroidal anti-inflammatory drug use and outcomes of #COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study
Nonsteroidal Anti-Inflammatory Drugs (#NSAIDs): Drug Safety Communication – Avoid Use of NSAIDs in #Pregnancy at 20 Weeks or Later
FDA is warning that use of NSAIDs around 20 weeks or later in pregnancy may cause rare but serious kidney problems in an unborn baby. This can lead to low levels of amniotic fluid surrounding the baby and possible complications. For prescription NSAIDs, FDA is requiring changes to the prescribing information to describe the risk… Continue reading Nonsteroidal Anti-Inflammatory Drugs (#NSAIDs): Drug Safety Communication – Avoid Use of NSAIDs in #Pregnancy at 20 Weeks or Later
Comparative evaluation of topical diclofenac sodium vs topical Ibuprofen in the treatment of #seborrheic keratosis.
In 2016, a case of seborrheic keratosis was successfully treated with diclofenac gel 3%. Diclofenac gel mechanism of action is most likely through induction of apoptosis. This study included 30 patients with multiple seborrheic keratosis. One lesion was treated with topical diclofenac sodium gel 1% and another lesion with topical ibuprofen gel applied twice daily… Continue reading Comparative evaluation of topical diclofenac sodium vs topical Ibuprofen in the treatment of #seborrheic keratosis.
Efficacy and safety of #anti-inflammatory agents for the treatment of major #depressive disorder: a systematic review and meta-analysis of randomised controlled trials
..Four studies explored the antidepressant effects of NSAIDs in addition to traditional antidepressants. In all four studies, celecoxib was added at the same dose (400 mg/day). Traditional antidepressants used were sertraline, fluoxetine and reboxetine. We combined these studies for a subgroup meta-analysis, finding that antidepressants combined with celecoxib were better than antidepressants alone, leading to a… Continue reading Efficacy and safety of #anti-inflammatory agents for the treatment of major #depressive disorder: a systematic review and meta-analysis of randomised controlled trials
2 Medical News 